Pharma Patent Cliff 2025 2030 Pharma Risks Biosimilars Strategies The industry’s ability to unlock the next wave of innovation and to continue its strong record of shareholder returns is at risk. a steep “patent cliff,” threatens revenues and will put pressure on margins, which are essential to funding ever more complex and costly r&d. Some of the best selling drugs in the world are facing a loss of exclusivity in key jurisdictions in what the sector calls “the patent cliff.” by 2032, losses of exclusivity for best selling.
Pharma Patent Cliff 2025 2030 Pharma Risks Biosimilars Strategies However, the proverbial cliff has never loomed as large over biopharma as it will over the remainder of this decade, as key patents are set to expire on billion dollar plus “blockbuster” drugs. The pharmaceutical industry operates on a high risk, high reward model predicated on a finite period of market exclusivity. the expiration of this exclusivity, commonly known as the “patent cliff,” is the single most disruptive and predictable event in a drug’s commercial lifecycle. Read evaluate’s latest report on portfolio tactics to scale the $300bn patent cliff. essential reading for pharma, biotech, and investment professionals, covering patent expiry risks, growth gaps, dealmaking trends, and strategic archetypes. In 2024, several leading pharmaceutical companies face a patent cliff, as some of their top selling drugs are set to lose patent protection. blockbuster medications from merck, bristol myers squibb, and johnson & johnson are among those at risk.
Patent Cliff 2025 Impact On Pharma Investors Read evaluate’s latest report on portfolio tactics to scale the $300bn patent cliff. essential reading for pharma, biotech, and investment professionals, covering patent expiry risks, growth gaps, dealmaking trends, and strategic archetypes. In 2024, several leading pharmaceutical companies face a patent cliff, as some of their top selling drugs are set to lose patent protection. blockbuster medications from merck, bristol myers squibb, and johnson & johnson are among those at risk. Between 2025 and 2030, nearly 200 blockbuster drugs will lose patent protection, triggering the most severe patent cliff in history and a catastrophic revenue hemorrhage. In december 2023, the pharma sued samsung bio for alleged patent infringement. regeneron also has a case against sandoz, seeking to block the generics developer from marketing its biosimilar. the pharma has also developed a high dose (hd) version of eylea to keep the product’s competitive edge. Big pharma teeters on the edge of a patent cliff that could strip away $300 billion — a sixth of the industry’s overall revenue — by 2030, according to an evaluate report. The pharmaceutical industry is staring down its most existential challenge in decades: a $300 billion patent cliff by 2028, as blockbuster drugs lose exclusivity and face generic and biosimilar.
Comments are closed.